Clinical Trials Sponsored by Enteris BioPharma Inc.

Total 458 results

Matinas Biopharma, Inc
Covance

Withdrawn

Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL (AMPLIFY)

Severe Hypertriglyceridemia
Seagen Inc.
Array BioPharma

Completed

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Cancer

Canada, United States
Alios Biopharma Inc.
Alexion

Completed

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Chronic Hepatitis C

France
Matinas BioPharma Nanotechnologies, Inc.

Withdrawn

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Vulvovaginitis | Candidiasis, Vulvovaginal | Vulvovaginal Candidiases | Yeast Infection | Yeast Infection Vaginal

United States
Immune Response BioPharma, Inc.

Unknown

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study (RAISE)

HIV

United States
Dance Biopharm Inc.

Completed

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes (Samba-02)

Type 2 Diabetes Mellitus
KinoPharma Inc.

Active, not recruiting

OM202JP Clinical Study of KNP2002

Common Wart

Japan
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
Mylan Inc.
Theravance Biopharma

Completed

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Chronic Obstructive Pulmonary Disease, COPD | Low Peak Inspiratory Flow Rate (PIFR)

United States
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

Hepatic Impairment

United States
Mylan Inc.
Theravance Biopharma

Completed

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

Cardiac Repolarization in Healthy Subjects

United States
Mylan Inc.
Theravance Biopharma

Completed

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United States
Crimson Biopharm Inc.

Not yet recruiting

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

Glioblastoma
Dance Biopharm Inc.

Completed

Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes (Samba-01)

Type 1 Diabetes Mellitus
Mylan Inc.
Theravance Biopharma

Completed

Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease, COPD

New Zealand
Mylan Inc.
Theravance Biopharma

Completed

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | COPD

United States
Mylan Inc.
Theravance Biopharma

Completed

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

Renal Impairment

United States
Mylan Inc.
Theravance Biopharma

Completed

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

COPD

New Zealand
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Anterios Inc.

Completed

Dose Finding Study In Subjects With Crow's Feet

Lateral Canthal Lines | Crow's Feet

United States
Anterios Inc.

Completed

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

Acne Vulgaris

United States
Anterios Inc.

Completed

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

Lateral Canthal Lines | Crow's Feet

United States
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Withdrawn

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta (Meteoroid)

Osteogenesis Imperfecta

United States
Spectrum Pharmaceuticals, Inc
CTI BioPharma

Terminated

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular | Follicular Lymphoma

United States
IVI Bilbao
Aytu BioPharma, Inc.

Withdrawn

Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men Whose Partners Will Undergo Through an Egg Donation Cycle (Mioxsys ox)

Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man)

Spain
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian (SIERRA)

Primary Peritoneal Carcinoma

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Relapsed or Refractory Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
Syneos Health
Oncolys BioPharma Inc

Unknown

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Melanoma Stage Iv | Melanoma Stage III

United States
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Crohn's Disease

United States
ARCA Biopharma, Inc.
Health Decisions

Completed

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

Arterial Occlusive Diseases | Thrombosis | Peripheral Vascular Diseases

United States
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
PDL BioPharma, Inc.

Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States
Anterios Inc.

Completed

Clinical Trial to Evaluate ANT-1401 in Crow's Feet

Lateral Canthal Lines | Crows Feet

United States
Anterios Inc.

Completed

Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis

Primary Axillary Hyperhidrosis

United States
Cystetic Medicines, Inc.
DevPro Biopharma

Recruiting

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People With Cystic Fibrosis (ABCI)

Cystic Fibrosis

Australia, New Zealand
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Completed

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 (Asteroid)

Osteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type I

United States, Canada, Denmark, France, United Kingdom
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

Metastatic Breast Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Ovarian Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Advanced Solid Tumor Malignancies

United States

Clinical Trials Sponsored by Enteris BioPharma Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations